IL6 and hydrops fetalis: Although many IL-6-targeted therapies were used in the treatment of rheumatologic diseases and immune checkpoint inhibitor-induced cytokine release syndrome (Kang et al., 2019), clinical trials especially aimed at the therapeutic effects of anti-IL-6 on HF have not been implemented.